met097
Peptideexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Apr 1, 2024 (NCT06857617)
Timeline
Indications
Mechanism of action
GLP1R agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07311850 | Phase 3 | Dec 29, 2025 | Metsera |
| NCT06973720 | Phase 2 | Apr 1, 2025 | Metsera |
| NCT06897202 | Phase 2 | Mar 14, 2025 | Metsera |
| NCT06924320 | Phase 1 | Mar 3, 2025 | Metsera |
| NCT06712836 | Phase 2 | Oct 24, 2024 | Metsera |
| NCT06857617 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2024 | Metsera |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Metsera | For profit | 6 | 6 | 3 | 2024 |
1 organizations
Page 1 / 1